Earth Science Tech, Inc. Shares Progress on its Cannabis (CBD) Patent Formulas

DORAL, Florida, July 10, 2018 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, as well as research and development, is pleased to share progress on the company’s CBD IP patent formula development program.


Mentioned in June, the Company currently developing three new CBD formulas and already under the provisory patent.


Two of them are very unique CBD formula products a neuron protector and a breast protector. The company is very bullish on these CBD formulas as the R&D done by the Centre de développement bioalimentaire du Québec (CDBQ) or Quebec Agrifood Innovation Center (QAIC) has been very promising. The team at CDBQ is highly experienced and able to employ the most effective and economical solutions to develop products with the best price-quality ratio on the market. CDBQ is now working on the final formulation that will include an as-yet undetermined natural protective agent to assure the longest possible shelf life of the CBD formula. Several alternatives are now being meticulously tested.


The third CBD formula is a new type of superfood with unique organoleptic properties never seen on the market. Formulated from a mix of hemp oil and other vegetal oil(s), and enriched with a highly potent antioxidant, this product is designed to improve the individuals antioxidant ingestion. The Company has developed this CBD formula with experts that have successfully developed products for some of the largest players in the food industry.


The Company also has two products in development as part of a Joint Venture with Bionatus Laboratório Botânico  of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc.


“We are already at work with Bionatus in Brazil and in Canada on the manufacture of the first product, Propovit enriched with ETST hemp oil. We are also working on a reformulation of Bionatus’ product,” stated ETST CEO and Chief Science Officer, Dr. Michel Aube. “The new formulation will see the product enriched with CBD to boost the suspected anti-inflammatory and bronchial-dilatation properties of the main natural ingredient – Guaco (Mikania glomerata) extract (


Guaco is a Brazilian plant widely used to help treat respiratory conditions. The Brazilian Health Regulatory Agency (ANVISA) has encouraged the use of Guaco, as its effectiveness has been proven by traditional use and the product is widely available OTC in Brazil. Guaco’s actions as an anti-inflammatory, an anti-edema agent, and a bronchodilator have been proven through in-vivo studies using extracts of Mikania glomerata.


ETST and Bionatus have planned a new product that will combine the effects of Mikania glomerata and Cannabis sativa oil for specific patients.  Details will be forthcoming shortly.


André Konan PhD , Director of the Laboratory Bionatus Pharmacognosique Inc. states: As we move forward in this project, research results on CBD as well as clinical trials on Guaco and Brazilian honey used in Propovit are increasingly being published. This allows us to better focus our research to bring more innovative products to the market.


The Company plans to share further updates on its CBD IP patent formula, research and development, Form 10 approval, and medical device updates as each progresses.


About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to  studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets, and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit:


ETST currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:


Earth Science Pharmaceutical
Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharma, Inc. (“ESP”), which is committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP’s CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
To learn more please visit:


Cannabis Therapeutics 
Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
To learn more please visit:  


KannaBidioid, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioiD, Inc. (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.
To learn more please visit:


Earth Science Foundation, Inc.
Earth Science Foundation, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Earth Science Foundation, Inc. (“ESF”), is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech, Inc’s effective CBD products to those in need.
To learn more please visit:


About Karmavore Superfoods
Born as a passion project by founder Brian Miller, a world renowned yoga teacher, health enthusiast and entrepreneur. Karmavore Superfoods is a superfood based health food company producing premium quality packaged snack foods using only the healthiest, most nutritionally dense ingredients available. Their mission is to make the tastiest and healthiest snacks possible. Their products are formulated by specifically choosing each ingredient based not only on its taste profile, but on its nutritional profile and how it interacts with our system. All of the products are organic, vegan, gluten free, low in sugar and refined sugar free. Not only do the products taste amazing, they leave you feeling great as well.
To learn more please visit:


SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Investor Relations Contact:
Dave Demarest
305.546.7640 Office

Company Contact:
Nickolas S. Tabraue
President, Director, & Chariman

Source: Earth Science Tech, Inc.